Key Takeaways HIMS plans to enter Canada in 2026, targeting unmet demand for affordable obesity treatments.Hims & Hers' $870 million notes offering will fund global growth, AI-powered care and strategic acquisitions.New care areas like sleep, fertility and cardiovascular expand HIMS' vertically integrated ecosystem.The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS) , is accelerating its healthcare ecosystem expansion through global reach, product diversification and the integration o ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In LifeMD To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in LifeMD between May 7, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIR ...

All right, newly installed Fed Governor Steven Myron is saying he favored a bigger rate cut at the recent FOMC meeting. Here with the latest on this story is our Fed correspondent Jennifer Shawnberger. Jen, good afternoon.miles. New Federal Reserve Governor Steven Myron said he favored a jumbosized rate cut at the central bank's policy meeting earlier this week because he doesn't see any inflation from tariffs and he favors a policy rate that does not restrict the economy nor spur it. Myron telling CNBC in ...

公司财务表现 - 第二季度收入同比增长25%至2.41亿美元，最近十二个月收入达7.52亿美元 [2] - 第二季度调整后税息折旧及摊销前利润为7000万美元，最近十二个月自由现金流为1.3亿美元 [2] - 公司股票交易价格约为自由现金流的30倍 [2] 业务战略与模式 - 业务从美妆扩展至皮肤、头发护理，并通过即将推出的品牌3 telehealth平台进入医疗级处方和非处方产品领域 [2] - 数据驱动的直接面向消费者模式形成一个自我强化的增长飞轮：用户洞察指导产品开发，驱动卓越效果并增强用户参与度 [4] - 利用超过6000万用户基础，以皮肤科作为高需求、高摩擦的切入点，解决消费者对传统方案不满及皮肤科医生资源有限的问题 [3] 增长催化剂与前景 - 品牌3以及未来的品牌4是主要增长催化剂，可能推动收入年增长率在2026年末超过25% [5] - 首席执行官和首席财务官强调可持续的复合增长，目标为20%的收入增长和税息折旧及摊销前利润利润率 [4] - 公司通过人工智能、计算机视觉技术和移动端指导提供个性化治疗方案，该方法具有差异化且可扩展 [3] 市场地位与验证 - 公司在美容和新兴医疗级健康护理市场定位为领先参与者 [2] - 尽管存在过往做空报告的质疑，但公司经过审计的财务报表、强劲的Trustpilot评分以及不断扩大的产品组合验证了其模式 [4] - 截至9月12日，公司股票交易价格为62.82美元，追踪市盈率为34.90 [1]

There are strong quantified results when Hims and Hers Health Inc (NYSE:HIMS) stock crosses above its 50-day moving average, with an average next-month return of 31.8% and an 83% win rate. HIMS has a nice-looking monthly graph, with pullbacks to its 12-month moving average earlier this month creating supreme buying opportunities. There was also a positive reaction to the company’s expansion of low-testosterone treatments, showing their efforts to expand beyond weight-loss drugs. Short interest is at a recor ...

Company outperforms internal projections while advancing investments, acquisitions, and strengthening its balance sheetVANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (CSE: NURS, OTC: HYDTF, FSE: SO6) (“Hydreight” or the “Company”), a mobile clinical network powered by a proprietary telehealth platform, pharmacy network, and medical director network across 50 states, today provided a corporate update highlighting stronger-than-expected order growth and recent stra ...

Accessibility StatementSkip Navigation PHILADELPHIA, Sept. 16, 2025 /PRNewswire/ -- Berger Montague PC, national plaintiffs' law firm, announces a class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) ("LifeMD" or the "Company") on behalf of investors who purchased or acquired shares during the period from May 7, 2025 through August 5, 2025(the "Class Period"). Investor Deadline: Investors who purchased or acquired LifeMD securities during the Class Period may, no later than October 27, 2025, seek to b ...

ToplineThe Food and Drug Administration sent warning letters to dozens of drug companies this month, including popular telehealth firm Hims & Hers, demanding they correct “false or misleading claims” about some of their products, targeting the companies just days after President Donald Trump signed an order designed to clamp down on direct-to-consumer drug advertising.Hims was one of dozens of companies that received the warning letters. (Photo illustration by Cheng Xin/Getty Images)Getty Images ...

The U.S. Food and Drug Administration has sent a warning letter to telehealth firm Hims & Hers Health regarding its compounded versions of Novo Nordisk's diabetes drug Ozempic and weight-loss treatment Wegovy. ...

文章核心观点 - 美国食品药品监督管理局向远程医疗巨头Hims & Hers Health发出警告信 指责其销售复合版司美格鲁肽产品的营销宣传存在误导性 导致公司股价单日下跌超过7% [1][2] FDA警告信内容 - FDA指出公司在网站上销售复合药物司美格鲁肽 并声称其产品使用与诺和诺德品牌药Ozempic和Wegovy"相同的活性成分" [1][2] - FDA认为这些宣传语暗示其产品与FDA批准的药物相同 但实际上复合药物并未经FDA批准 因此属于虚假或误导性宣传 产品被认定为冒牌货 [2] - FDA要求公司在15天内对指控作出回应 或提供证据证明其产品未违反法律 [5] 公司业务与产品背景 - Hims & Hers Health是一家远程医疗巨头 业务包括复合药物 公司销售护肤 性健康和防脱发产品 [3] - 公司于2024年5月推出复合司美格鲁肽后知名度大增 当时品牌药司美格鲁肽正处于短缺状态 复合药物制造商得以填补供应缺口 [3][4] - FDA于今年2月确定短缺结束 但公司目前利用漏洞继续销售个性化剂量的司美格鲁肽 [4] 市场反应与股价表现 - 受FDA警告信影响 公司股价在盘中交易中下跌超过7%至49.91美元 股价下探至50日移动平均线支撑位 [2] - 公司股价今年波动剧烈 2月曾创下近73美元的历史高点 4月回落至24美元附近 7月反弹至70美元以上 近期又跌至41美元附近 [6] - 截至周一收盘 公司股价较9月2日的低点已反弹32% [6]